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ABSTRACT
Since January 1996, we have administered myeloablative therapy followed by infusion of unrelated umbilical
cord blood cells in 57 adult patients with high-risk disease. The median age was 31 years (range, 18-58 years),
and the median weight was 70 kg (range, 46-110 kg). Two patients were treated for genetic disorders and 55
for advanced hematologic malignancies. The preparative regimens were total body irradiation or busulfan
based, both with antithymocyte globulin. HLA matching between donor and recipient was 3 of 6 in 3 patients,
4 of 6 in 44 patients, 5 of 6 in 8 patients, and 6 of 6 in 2 patients. The median nucleated cell dose was 1.50 
107/kg (range, 0.54-2.78  107/kg), and the median CD34 cell dose was 1.37  105/kg (range, 0.02-12.45 
105/kg). All patients received granulocyte colony-stimulating factor after transplantation until neutrophil
recovery. Graft-versus-host disease prophylaxis consisted of cyclosporine and steroids. The median number of
days to an absolute neutrophil count of 500/L was 26 (range, 12-55 days). The median time to an untransfused
platelet count of >20 000/L was 84 days (range, 35-167 days). Seventeen patients developed grade II to IV
acute GVHD. The median survival of the entire group was 91 days (range, 10-2251 days). Eleven patients were
alive at a median follow-up of 1670 days (range, 67-2251 days), 1 with autologous recovery and 1 with relapsed
lymphoma. The actuarial projected 3-year survival is 19%. Infection was the primary cause of death. These
results suggest that unrelated umbilical cord blood transplantation is a viable option for adult patients and
should be explored in patients with earlier-stage disease.
© 2003 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
Transplantation of allogeneic hematopoietic pro-
enitor cells is potentially curative therapy for a num-
er of hematologic malignancies, bone marrow failure
yndromes, and inherited metabolic disorders [1]. The
pplication of allogeneic transplantation is limited by
onor availability such that only approximately one
hird of otherwise appropriate candidates have suit-
bly matched family donors. Alternative donors in-
lude mismatched family members or matched unre-
ated donors, but these approaches are complicated by
n increased risk of graft-versus-host disease (GVHD) n
72nd often a prolonged time to identify and procure
onor grafts [2]. Umbilical cord blood contains high
umbers of hematopoietic progenitor cells [3]. Since
he ﬁrst successful umbilical cord blood transplant was
eported in 1989 in a 6-year-old child with Fanconi
nemia, umbilical cord blood has been used to restore
one marrow function after myeloablative therapy in
oth related and unrelated recipients, and cord blood
anks have been established [4-10].
Most of the transplantations have been performed
n pediatric patients because of concerns regarding
ngraftment in adult patients with the relatively smalloi:10.1016/j.bbmt.2003.08.007umbers of cells obtained from individual cord blood
units, although successful engraftment has been re-
ported in isolated adult patients [11,12]. The early
experience with umbilical cord blood transplantations
at Duke University Medical Center was reported in
1996 and included 24 pediatric patients and 1 adult
with Fanconi anemia complicated by acute myeloge-
nous leukemia [13]. The patient was 23 years old and
weighed 44 kg. The patient engrafted and developed
grade III GVHD, which resolved. She did well until
approximately 4 years after transplantation, when she
developed and died of a secondary malignancy (squa-
mous cell carcinoma of the head and neck).
Recently 2 reports [14,15] have examined the out-
come of unrelated umbilical cord blood transplanta-
tions in adults. A multicenter study described 68 pa-
tients treated with myeloablative therapy and rescued
with unrelated umbilical cord blood cells [14]. Seventy-
one percent of the grafts were mismatched for at least
2 HLA antigens. The probability of neutrophil recov-
ery was 90%, and grades II to IV acute GVHD oc-
curred in 60% of the patients. Eighteen of the 68
patients were alive and disease free with a median
follow-up of 22 months. In another single-institution
study of 22 adult patients, the 1-year disease-free sur-
vival was 53%, with a 32% incidence of acute GVHD
[15].
Since 1996, we have performed transplantation in
57 adult patients with unrelated umbilical cord blood
cells after myeloablative therapy at Duke University
Medical Center; these patients are the subject of this
report. Nineteen of the patients in this report were
included in the multicenter study published in 2001
[14]. We have extended the follow-up on surviving
patients from that study by 22 months and have in-
cluded an additional 38 patients in this report.
PATIENTS AND METHODS
Patient Eligibility
The treatment protocol was approved by the In-
stitutional Review Board of Duke University Medical
Center. Patients were eligible if they had a condition
appropriate for allogeneic hematopoietic progenitor
cell transplantation and did not have a 6 of 6 or 5 of 6
related donor, if they did not have a 6 of 6 matched
unrelated donor, or if their condition did not allow the
time required for identiﬁcation and procurement of a
matched unrelated donor. All patients signed an ap-
proved consent form.
Donor Selection
Cord blood searches were performed through the
Placental Blood Program at the New York Blood
Center and more recently through the National Mar-
row Donor Program and the Cord Blood Transplan-
tation Study cord blood banks. Forty-three units were
obtained from the New York Blood Center, 12 from
the Cord Blood Transplantation Study bank, and 2
from the National Marrow Donor Program. Units
were chosen according to degree of HLA matching
and cell dose. HLA class I antigens were identiﬁed
according to serologic or low-resolution DNA typing,
and class II antigens were identiﬁed according to
high-resolution typing of DRB1. Genetic identity at
DRB1 took precedence over class I identity. If more
than 1 similarly matched unit was available, then the
unit with the highest cell dose was used. Units were
scored for matching at class I A and B antigens and
class II DRB1 alleles. All units contained a minimum
cryopreserved nucleated cell dose of 1  107/kg re-
cipient weight.
Preparative Regimen and Transplantation
Twenty-nine patients were prepared with a com-
bination of total body irradiation (TBI; 13.5 Gy in 9
fractions over 5 days from day 9 to day 5; lung
dose attenuated to 10 Gy; 4-Gy testicular boost in 2
days in male patients with leukemia or myelodyspla-
sia), melphalan 45 mg/m2/d for 3 days from day 4 to
day 2, and antithymocyte globulin (ATG) 30 mg/
kg/d for 3 days from day 3 to day 1. Seventeen
patients who were not candidates for irradiation re-
ceived busulfan 4 mg/kg/d for 4 days on day8 to day
5 as a substitute for TBI. The 2 patients with inher-
ited disorders were treated with busulfan for 4 days on
day 9 to day 6, cyclophosphamide (CY) 50 mg/
kg/d for 4 days on day 4 to day 2, and ATG for 3
days on day 3 to day 1. One patient with myelo-
dysplastic syndrome and a history of Fanconi anemia
was treated with thoracoabdominal radiation, low-
dose CY (10 mg/kg/day for 4 days), and ATG, and 8
patients with chronic myelogenous leukemia were
treated with TBI, CY (60 mg/kg/d for 2 days), and
ATG. The cryopreserved cord blood units were trans-
ported to the transplant center in a dry shipper and
stored in the vapor phase of liquid nitrogen. The units
were thawed in the laboratory and washed with 10%
dextran and 5% human albumin before infusion, as
previously described [16]. Cell counts, viability, and
CD3 and CD34 cell counts were determined at the
time of thawing. The cord blood was infused through
a central line at a rate of 1 to 3 mL/min on day 0.
GVHD Prophylaxis and Supportive Care
Patients received a combination of cyclosporine
and methylprednisolone for GVHD prophylaxis, ex-
cept for 1 patient who received cyclosporine alone. All
patents received methylprednisolone 2 mg/kg/d on
day 3 to day 0 as premedication for ATG. The ﬁrst
5 patients were treated with methylprednisolone 10
mg/kg/d on days 5 through 7, 5 mg/kg/d on days 8
through 10, 3 mg/kg/d on days 11 through 13, and 2
Cord Blood Transplants in Adults
773BB&MT
mg/kg/d on days 14 through 17, followed by a 10%
per week taper. In subsequent patients, the methyl-
prednisolone dose was decreased to 1 mg/kg/d on days
0 through 4 and 2 mg/kg/d on days 5 through 20,
followed by a taper of 0.2 mg/kg/wk. Acute and
chronic GVHD were diagnosed and graded by stan-
dard criteria. Grade II to IV acute GVHDwas initially
treated with high-dose steroids followed by other
agents at the discretion of the treating physician. Pa-
tients were housed in reverse-isolation rooms with
high-energy particulate ﬁltration. Granulocyte colo-
ny-stimulating factor was administered at 5 g/kg/d
until the absolute neutrophil count (ANC) was
10 000/L for 3 consecutive days and was then
tapered by 50% every 3 days as long as the ANC
remained 5000/L. Platelets were transfused for
counts 10 000/L or bleeding, and packed red
blood cells were administered for hematocrit 30%.
Patients received prophylactic low-dose amphotericin
B (0.15 mg/kg/d) from day 1 through day 100 and
received prophylactic oral antibiotics until engraft-
ment. Neutropenic fever was treated with broad-spec-
trum antibiotics. Heparin 100 U/kg/d was given as a
continuous intravenous infusion from the start of the
preparative regimen until engraftment for hepatic
veno-occlusive disease prophylaxis. Trimethoprim/
sulfamethoxazole was administered before transplan-
tation for Pneumocystis carinii prophylaxis. Patients re-
ceived intravenous immune globulin 250 mg/kg/wk
through day 100. After September 1997, all patients
were treated with a course of rotating prophylactic
oral antibiotics consisting of a quinolone for 1 week, a
cephalosporin for 1 week, and off for 1 week; the cycle
was repeated from engraftment until day 100. All
patients who were serologically positive for herpes
simplex virus, varicella-zoster virus, or cytomegalovi-
rus (CMV) received acyclovir 250 mg/m2 intrave-
nously every 12 hours from day 0 through engraft-
ment. Weekly CMV antigens or DNA testing was
obtained through day 100, and patients with positive
results were treated with ganciclovir (5 mg/kg twice
daily for 2 weeks, followed by 5 mg/kg daily Monday
through Friday for 10 weeks) and continued on intra-
venous immune globulin.
Statistical Analysis
This report is a retrospective analysis of 57 se-
quential adult patients treated at Duke University
Medical Center. We estimated overall and event-free
survival through June 30, 2002, according to the
Kaplan-Meier product-limit method [17] and applied
the log-rank test to compare 2 distributions. We cal-
culated event-free survival as time from transplanta-
tion to disease progression, graft failure (primary or
secondary), autologous bone marrow recovery, or
death from any cause, whichever occurred ﬁrst. Pri-
mary graft failure was deﬁned as the absence of ade-
quate hematopoiesis, as evidenced by bone marrow
cellularity 5%, white blood cell count 500/L, or
ANC 100/L by day 42 or platelet count 10 000/
L by day 120 with an absence of megakaryocytes in
the bone marrow. Secondary graft failure was deﬁned
as the loss of previously documented donor cell en-
graftment. Patients who were alive and disease free
were censored at the date of the last follow-up visit.
Overall survival was calculated from the time of trans-
plantation to death, and patients who were alive were
censored at the date of the last follow-up visit. The
Wilcoxon rank-sum test was used to compare the
cryopreserved cell dose, the nucleated cell dose in-
fused, and the CD34 cell dose infused in patients who
achieved neutrophil engraftment and those who did
not and to compare the same variables in patients who
survived event free and those who did not. We used
Cox proportional hazards models to determine which
independent variables, including age, sex of patient,
sex of donor, HLA match, CMV status, weight, diag-
nosis, cryopreserved cell dose, cell dose infused, and
CD34 cell dose, predict overall or event-free survival.
Each variable was entered in turn as an independent/
univariate factor. We also used each variable as an
independent factor in logistic modeling to predict the
chance of a patient recovering platelets (untransfused
platelet count 20 000/L) or achieving ANC
500/L by day 42. Each of the independent vari-
ables listed previously was used to predict ANC
500/L and platelet recovery. Patients who died
before day 42 and had not achieved ANC or platelet
recovery were excluded from these analyses. A P value
.05 was considered statistically signiﬁcant.
RESULTS
Patient Characteristics
Fifty-seven patients underwent transplantation
between January 1996 and January 2002. The median
age was 31 years (range, 18-58 years), and the median
weight was 70 kg (range, 46-110 kg). Details of patient
characteristics are described in Table 1. Four patients
had relapsed after autologous and 2 after allogeneic
transplantations. Thirty-six patients were serologi-
cally positive for CMV before transplantation, and 21
were negative.
Graft Characteristics
Details of HLA matching, donor and recipient sex
match, and cell dose are described in Table 2. No
donor/recipient pairs were mismatched at both
HLA-DR loci.
Engraftment and Chimerism
The median time to an ANC of 500/L was 26
days (range, 12-55 days) in 41 evaluable patients. Four
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patients did not engraft, 3 patients died of infection, 2
died of alveolar hemorrhage, and 1 each died of veno-
occlusive disease, congestive heart failure, and multi-
organ failure before reaching an ANC of 500/L; 4
patients had autologous recovery. The Kaplan-Meier
estimate of median time to ANC 500/L was 28
days (Figure 1A). Nine (18%) of 49 patients who
survived at least 42 days did not engraft with donor
cells, although 1 additional patient did recover with
donor cells on day 55. Four of the 8 patients who
never engrafted donor cells had autologous recovery.
The median number of days to an untransfused
platelet count of 20 000/L was 84 (range, 35-167
days) in 19 evaluable patients. Thirty-eight patients did
not achieve a platelet count of 20 000/L. Fourteen
died of infection, 4 of multiorgan failure, 4 of graft
failure, 3 of diffuse alveolar hemorrhage, 3 of acute
GVHD, and 1 each of graft rejection, adult respiratory
distress syndrome, congestive heart failure, chronic
GVHD, veno-occlusive disease, and relapse; 4 patients
had autologous recovery. The Kaplan-Meier estimate of
Table 1. Patient Characteristics
Characteristic No. of Patients (%)
Age, y
18-29 25 (44%)
30-39 14 (25%)
40-49 11 (19%)
50-59 7 (12%)
Median (range) 31 (18-58)
Sex
Male 33
Female 24
Weight, kg
40-59 10 (18%)
60-69 16 (28%)
70-79 15 (26%)
80-89 10 (18%)
>90 6 (10%)
Median (range) 70 (46-110)
Diagnosis
Acute myelogenous leukemia
First complete remission 1
Third complete remission 1
Induction failure 1
Relapse 16
Secondary acute myelogenous leukemia 2
Acute lymphoblastic leukemia
First complete remission (Ph) 1
Second complete remission 5
Induction failure 1
Relapse 6
Chronic myelogenous leukemia
Chronic phase 2
Accelerated phase 5
Blast crisis 3
Myelodysplastic syndrome 3
Myelofibrosis 2
Non-Hodgkin lymphoma 4
Chronic lymphocytic leukemia 1
Prolymphocytic leukemia 1
Diamond-Blackfan anemia 1
Adrenoleukodystrophy 1
Ph indicates Philadelphia chromosome–positive.
Table 2. Graft Characteristics
Variable Data
HLA match, No. patients (%)
6/6 2 (4%)
5/6 8 (14%)
4/6 44 (77%)
3/6 3 (5%)
DR mismatch 26 (46%)
Donor/recipient sex,
No. patients (%)
F3F 14 (25%)
F3M 16 (28%)
M3M 14 (25%)
M3F 10 (17%)
Unknown 3 (5%)
Median nucleated cell dose
cryopreserved (range) 2.12  107/kg (1.11-4.42  107/kg)
Median nucleated cell dose
infused (range) 1.50  107/kg (0.54-2.78  107/kg)
Median CD34  cell dose
infused (range) 1.37  105/kg (0.02-12.45  105/kg)
Figure 1. Neutrophil and platelet engraftment. Kaplan-Meier es-
timates of the probability of achieving an ANC of500/L (A) and
an untransfused platelet count 20 000/L (B).
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the median time to an untransfused platelet count of
20 000/L was 117 days (Figure 1B).
The median cryopreserved cell dose in the 41
patients who achieved an ANC of 500/L was
2.12  107/kg (range, 1.25-4.42  107/kg), compared
with 2.11  107/kg (range, 1.11-4.22  107/kg) in the
patients who died without achieving an ANC of
500/L or had autologous recovery (P  .34). The
median infused nucleated cell dose in the patients who
achieved an ANC of 500/L was 1.60  107/kg
(range, 0.65-2.78  107/kg), compared with 1.44 
107/kg (range, 0.54-2.64 107/kg) in the patients who
did not (P  .32). The median infused CD34 cell
dose in the patients who achieved an ANC of
500/L was 1.52  105/kg (range, 0.14-12.45 
105/kg), compared with 1.16  105/kg (range, 0.02-
4.95  105/kg) in the patients who did not (P  .19).
These differences were not statistically signiﬁcant.
Chimerism analysis was available on 33 of the 41
patients evaluable for neutrophil engraftment. Donor
engraftment ranged from 82% to 99% in 5 patients,
and the other 28 were 100% donor by HLA typing
(serologic for class I and molecular for class II), ﬂuo-
rescence in situ hybridization for sex chromosomes, or
restriction fragment length polymorphism analysis of
polymerase chain reaction microsatellite ampliﬁca-
tions. Five of the 8 patients for whom chimerism
studies were not available developed acute GVHD,
which was presumed evidence of donor cell engraft-
ment. An additional 4 patients were 100% recipient at
the time of neutrophil recovery: 1 had Philadelphia
chromosome–positive cells consistent with residual or
recurrent chronic myelogenous leukemia. No other
patient had residual disease at the time of engraftment
or death before engraftment.
Event-Free and Overall Survival
The median event-free survival of the entire group
was 87 days, with a range of 10 to 2251 days. The
median overall survival was 91 days, with a range of 10
to 2251 days. Eleven patients are alive with a median
follow-up of 1670 days (range, 67-2251 days). One of
these patients developed recurrent non-Hodgkin lym-
phoma on day 425, and 1 has autologous marrow
recovery without evidence of relapse. The estimated
event-free survival is 15% (Figure 2A), and overall
survival was 19% at 3 years (Figure 2B).
The median infused nucleated cell dose in the 9
patients who survived event free was 2.07  107/kg
(range, 0.65-2.75  107/kg), compared with 1.50 
107/kg (range, 0.54-2.78 107/kg) in the patients who
experienced an event (P  .41). The median infused
CD34 cell dose in the 9 patients who survived event
free was 2.27  105/kg (range, 0.74-12.45  105/kg),
compared with 1.15  105/kg (range, 0.02-11.79 
105/kg) in the patients who experienced an event (P 
.32). These differences were not statistically signiﬁ-
cant.
Graft-versus-Host Disease
Forty-one patients engrafted and survived beyond
30 days and were evaluable for acute GVHD. Seven-
teen patients (30%) developed acute GVHD (14%
grade II and 16% grade III or IV) at a median of 32
days after transplantation, with a range of 13 to 86
days. Organ involvement included skin only in 4 pa-
tients; gut only in 4 patients; liver only in 1 patient;
skin and gut in 6 patients; and skin, gut, and liver in 2
patients. Of the 41 patients at risk for acute GVHD, 1
of 3 patients with a 3 of 6 HLA match, 11 of 29
patients with a 4 of 6 HLA match, 4 of 7 patients with
a 5 of 6 HLA match, and 1 of 2 patients with a 6 of 6
HLA match developed GVHD. Three (18%) of 17
patients with acute GVHD are alive, whereas 7 (29%)
of 24 patients without acute GVHD survived. Eight of
25 patients who survived 100 days developed
Figure 2. Event-free and overall survival. Kaplan-Meier estimate of
event-free (A) and overall (B) survival of 57 adult patients who
underwent transplantation with unrelated umbilical cord blood.
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chronic GVHD (4 de novo, 2 after recovery from
acute GVHD, and 2 progressing from acute GVHD),
which was fatal in 2 cases. Five surviving patients have
chronic GVHD, which is limited in 2 patients (skin
only) and extensive in 3 (skin and gut).
Toxicity and Causes of Death
Infection (bacterial, viral, and fungal) was the most
common toxicity after unrelated umbilical cord blood
transplantation. One hundred forty-eight infections
were documented in these 57 patients by culture,
histopathology, or CMV DNA hybridization, includ-
ing 83 bacterial, 38 viral, and 26 fungal infections and
1 mycobacterial infection. Only 1 patient died of viral
infection (CMV). Most viral infections were reactiva-
tion of CMV, herpes simplex virus, or varicella-zoster
virus or cystitis secondary to polyoma virus. Forty-six
patients have died: 9 of fungal infection, 8 of relapsed
leukemia (2 after autologous marrow recovery), 7 of
bacterial infections, 5 of graft failure and infection (4
fungal and 1 CMV), 5 of multiorgan failure/VOD, 4
of acute GVHD, 4 of pulmonary hemorrhage, 2 of
chronic GVHD, and 1 each of adult respiratory dis-
tress syndrome and congestive heart failure. The 100-
day nonrelapse mortality was 50%.
Prognostic Factors
We used Cox proportional hazards models to de-
termine which independent variables, including age,
sex of patient, sex of donor, HLA match, CMV status,
weight, diagnosis, cryopreserved cell dose, cell dose
infused, and CD34 cell dose, predict overall or event-
free survival. We ﬁtted logistic regression models to
predict the chance of a patient recovering platelets
(untransfused platelet count 20 000/L) or achiev-
ing ANC 500/L by day 42. Age dichotomized at
the median of 31 years was a signiﬁcant predictor of
event-free survival (P  .019; Figure 3), and the in-
fused CD34 cell dose was signiﬁcant for platelet re-
covery (P  .0083; Figure 4). Generally, the higher
the CD34 cell dose, the better chance a patient had of
recovering platelets.
Figure 3. Event-free survival according to age. Kaplan-Meier estimate of event-free survival in patients 31 years (the median age) compared
with older patients (P  .019).
Figure 4. Platelet engraftment according to CD34 cell dose.
Kaplan-Meier estimates of the probability of achieving an untrans-
fused platelet count 20 000/L in patients who underwent trans-
plantation with less than or more than the median CD34 cell dose
of 1.37  105/kg (P  .0083).
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DISCUSSION
Unrelated umbilical cord blood transplantation
has been shown to be equivalent to unrelated donor
bone marrow transplantation in children, but experi-
ence with cord blood transplantations for adults is
limited [17]. Since January 1996, we have performed
unrelated umbilical cord blood transplantations in 57
adult patients with hematologic malignancies and in-
herited disorders. The median numbers of nucleated
and CD34 cells infused were approximately 1 log
lower than the cell doses administered with allogeneic
bone marrow or peripheral blood hematopoietic pro-
genitor cell transplants. Forty-one evaluable patients
engrafted neutrophils at a median of 26 days after
transplantation. The time to platelet transfusion inde-
pendence was delayed to 84 days. These results are
similar to engraftment times previously reported in
studies of cord blood transplantation in primarily pe-
diatric patient populations [5,13,18]. In these studies,
neutrophil recovery was correlated with the number
of nucleated cells infused at the time of transplanta-
tion. There was a nonsigniﬁcant trend toward more
rapid engraftment with increased CD34 cell num-
bers in 1 study [13]. In our current study, there was no
clear association between nucleated cell dose and en-
graftment, but there was an association between
higher CD34 cell doses and more rapid platelet en-
graftment. In 2 recent multicenter reports with more
patients on cord blood transplantation in adults, nu-
cleated cell dose was associated with neutrophil and
platelet engraftment [14,19]. In our study, patients
who underwent transplantation with 1.37  105
CD34 cells per kilogram had more rapid platelet
recovery. In the multicenter study by Laughlin et al.
[14], neutrophil engraftment was faster in patients
who underwent transplantation with a cryopreserved
nucleated cell dose 1.87  107/kg, and event-free
survival was improved in patients who received
1.2  105 CD34 cells per kilogram. In that study,
the CD34 cell count was not available when donor
units were chosen but was determined at the time of
thawing before infusion. The CD34 cell dose is now
determined before cryopreservation by most cord
blood banks and is available when units are chosen for
a particular patient. In the report by Rocha et al. [19],
an infused nucleated cell dose of 1.7  107/kg was
associated with more rapid engraftment and improved
survival. On the basis of the results of these reports
and our study, it is reasonable to suggest that cord
blood units for transplantation in adult patients con-
tain a cryopreserved cell dose of at least 1.8  107
nucleated cells per kilogram and 1.2  105 CD34
cells per kilogram.
Only 2 patient and donor pairs were completely
HLA-matched at high resolution, whereas most were
mismatched at 2 loci. Twenty-six patient and donor
pairs were mismatched at 1 DR locus, but none was
mismatched at both DR loci. Seventeen patients (30%
of the evaluable patients) developed grade II to IV
acute GVHD (16% grade III or IV); this rate is less
than that reported for matched unrelated donor mar-
row transplantations before the use of high-resolution
DNA typing and is similar to that currently reported
with high-resolution matching [2,20,21]. The inci-
dence of acute GVHD is signiﬁcantly lower than ex-
pected considering the degree of HLA mismatch and
the age of the patients in this study. In children, the
incidence of GVHD has been shown to be less in
recipients of HLA-matched sibling cord blood trans-
plants compared with HLA-matched sibling marrow
transplants [22]. The etiology of the lower incidence
of GVHD with cord blood cells is an area of intense
investigation but may be related to the biological ac-
tivity of cord blood T lymphocytes or lack thereof,
including decreased cytotoxic T-cell activity after al-
logeneic stimulation and decreased proliferation to
secondary allogeneic stimulation [23].
There is a concern that cord blood grafts may also
not mediate a graft-versus-leukemia effect, resulting
in increased relapse rates after transplantation; how-
ever, relapse rates have not been higher than expected
in reports to date [5,13,18,22]. In our series, only 7 of
25 patients who engrafted and survived at least 100
days experienced a relapse of their underlying hema-
tologic malignancy. Two other patients had autolo-
gous recovery and subsequently relapsed. The 2 pa-
tients who underwent transplantation for inherited
disorders remain alive and well 3 years after trans-
plantation. Previous studies have reported a relatively
increased number of CD56 natural killer cells after
umbilical cord blood transplantations, and natural
killer cells have been shown to potentially mediate a
graft-versus-leukemia effect after marrow transplanta-
tion [13,24,25].
Ten patients (19%) remain alive and disease free
at a median follow-up of approximately 4.5 years. One
patient with AML had autologous recovery but re-
mains without evidence of relapse. These results using
unrelated and mismatched stem cells are comparable
to the early results reported with matched unrelated
donor marrow transplants, in which patients older
than 18 years with poor-risk hematologic malignan-
cies had an actuarial survival of approximately 12%
[14]. Forty-six of the patients in our study had ad-
vanced hematologic malignancies, including 6 who
had relapsed after prior transplantation procedures.
Our results also compare favorably with those re-
ported with the use of T cell–depleted haploidentical
related donors [26] and with other reports of cord
blood transplantations in adults [14,20]. Another
study from Spain reported a 53% 1-year survival in 22
adult patients undergoing unrelated umbilical cord
blood transplantations [15]. In that study, however, 13
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patients had either chronic myelogenous leukemia in
the ﬁrst chronic phase or acute leukemia in ﬁrst re-
mission. Patients under the age of 30 had signiﬁcantly
better disease-free survival, and the oldest patient was
46 years old, whereas 13 of our patients were older
than 45 years, and 7 were older than 50 years. In our
study, age 32 years was also a predictor of improved
event-free survival.
The major toxicity in this study was infection, with
148 clinically signiﬁcant positive cultures in 57 pa-
tients. Infection was a direct cause of death in 21 of the
46 deaths and was a signiﬁcant cause of morbidity in
most patients. Seven deaths due to bacterial infection
occurred after engraftment of neutrophils, despite the
prolonged use of granulocyte colony-stimulating fac-
tor. Since September 1997, we have administered a
course of rotating oral antibiotics to all adult cord
blood transplant patients through day 100 and have
not seen additional deaths from bacterial infection
after neutrophil recovery. The incidence of fungal and
yeast infections after engraftment was increased after
the institution of prophylactic antibiotics (11% versus
45%), but fungal infection was the primary cause of
death in only 3 patients. The etiology of the increased
incidence of infection in engrafted umbilical cord
blood recipients is unknown, but it may be related
to delayed immune reconstitution and neutrophil
dysfunction [13,24,27-29]. Our current protocol uses
tacrolimus and minidose methotrexate for GVHD
prophylaxis in an attempt to reduce the immunosup-
pression associated with prolonged steroid administra-
tion [30,31].
In summary, our results and those of others dem-
onstrate that rescue with unrelated mismatched um-
bilical cord blood after myeloablative therapy in adults
is feasible and results in long-term engraftment and
disease-free survival in a group of high-risk patients
with hematologic malignancies and inherited disor-
ders and should be considered for younger patients
with earlier-stage disease. These transplants are asso-
ciated with a lower-than-expected risk of GVHD
without an increased risk of relapse. The application
of this therapy is still limited to a signiﬁcant degree by
the relatively lower cell doses in cord blood units.
Studies are under way to evaluate the use of ex vivo
expansion of cord blood cells and combinations of
multiple cord blood units to make the procedure avail-
able to more patients [32,33].
ACKNOWLEDGMENTS
We would like to acknowledge the efforts of the
nursing staffs of the pediatric and adult bone marrow
transplant inpatient units and outpatient clinics, the
pediatric and adult nurse practitioners and nurse cli-
nicians, the pediatric and adult hematology-oncology
fellows, the umbilical cord blood search coordinators,
the staff of the bone marrow transplant clinical labo-
ratory, and the radiation oncology therapy staff, phys-
icists, and dosimetrists in the care of these patients.
We would also like to acknowledge the pioneering
efforts in cord blood banking of Dr. Pablo Rubinstein
and his colleagues at the New York Blood Center.
REFERENCES
1. Appelbaum FR. The use of bone marrow and peripheral blood
stem cell transplantation in the treatment of cancer. CA Cancer
J Clin. 1996;43:131-136.
2. McGlave PB, Shu XO, WenW, et al. Unrelated donor marrow
transplantation for chronic myelogenous leukemia: 9 years’
experience of the National Marrow Donor Program. Blood.
2000;95:2219-2225.
3. Broxmeyer HE, Hangoc G, Cooper S, et al. Growth charac-
teristics and expansion of human umbilical cord blood and
estimation of its potential for transplantation in adults. Proc
Natl Acad Sci U S A. 1992;89:4109-4113.
4. Gluckman E, Broxmeyer HE, Auerbach AD, et al. Hematopoi-
etic reconstitution in a patient with Fanconi’s anemia by means
of umbilical cord blood from an HLA-identical sibling. N Engl
J Med. 1989;321:1174-1178.
5. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of
cord-blood transplantation from related and unrelated donors.
N Engl J Med. 1997;337:373-381.
6. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluck-
man E. Allogeneic sibling umbilical cord blood transplantation
in children with malignant and non-malignant disease. Lancet.
1995;346:214-219.
7. Wagner JE, Rosenthal J, Sweetman R, et al. Successful trans-
plantation of HLA-matched and HLA-mismatched umbilical
cord blood from unrelated donors: analysis of engraftment and
acute graft-versus-host disease. Blood. 1996;88:795-802.
8. Rubinstein P, Rosenﬁeld RE, Adamson JW, Stevens CE.
Stored placental blood for unrelated bone marrow reconstitu-
tion. Blood. 1993;81:1679-1690.
9. Rubinstein P, Adamson JW, Stevens C. The Placental/Umbil-
ical Cord Blood Program of the New York Blood Center: a
progress report. Ann N Y Acad Sci. 1999;872:328-334.
10. Gluckman E, Rocha V, Chastang C. Cord blood banking and
transplant in Europe. Bone Marrow Transplant. 1998;22(suppl
1):S68-S74.
11. Laporte J-P, Gorin N-C, Rubinstein P, et al. Cord-blood
transplantation from an unrelated donor in an adult with
chronic myelogenous leukemia. N Engl J Med. 1996;335:167-
170.
12. Deliliers GL, Soligo D, Della Volpe A, et al. Unrelated mis-
matched cord blood transplantation in an adult with secondary
AML. Bone Marrow Transplant. 1996;18:469-472.
13. Kurtzberg J, Laughlin M, GrahamML, et al. Placental blood as
a source of hematopoietic stem cells for transplantation into
unrelated recipients. N Engl J Med. 1996;335:157-166.
14. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic en-
graftment and survival in adult recipients of umbilical cord
blood from unrelated donors. N Engl J Med. 2001;344:1815-
1822.
15. Sanz GF, Saavedra S, Planelles D, et al. Standardized, unrelated
donor cord blood transplantation in adults with hematologic
malignancies. Blood. 2001;98:2332-2338.
Cord Blood Transplants in Adults
779BB&MT
16. Rubinstein P, Dobrila L, Rosenﬁeld RE, et al. Processing and
cryopreservation of placental/umbilical cord blood for unre-
lated bone marrow reconstitution. Proc Natl Acad Sci U S A.
1995;92:10119-10122.
17. Barker JN, Davies SM, Defor T, Ramsay NKC, Weisdorf DJ,
Wagner JE. Survival after transplantation of 0-3 HLA-mis-
matched unrelated donor umbilical cord blood is equivalent to
that of HLA-identical unrelated donor bone marrow. Blood.
2000;96:206a, (abstr.).
18. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among
562 recipients of placental-blood transplants from unrelated
donors. N Engl J Med. 1998;339:1565-1577.
19. Rocha V, Arcese W, Sanz G, et al. Prognostic factors of out-
come after unrelated cord blood transplant in adults with he-
matologic malignancies. Blood. 2000;96:587a, (abstr.).
20. Kernan N, Bartsch G, Ash R, et al. Analysis of 462 transplan-
tations from unrelated donors facilitated by the National Mar-
row Donor Program. N Engl J Med. 1993;328:593-602.
21. Petersdorf EW, Longton GM, Anasetti C, et al. Deﬁnition of
HLA-DQ as a transplantation antigen. Proc Natl Acad Sci U S A.
1996;93:15358-15363.
22. Rocha V, Wagner JE, Sobocinski KA, et al. Graft-versus-host
disease in children who have received a cord blood or bone
marrow transplant from an HLA-identical sibling. N Engl
J Med. 2000;342:1846-1854.
23. Broxmeyer HE, Smith FO. Cord blood stem cell transplanta-
tion, In: Thomas ED, Blume KG, Forman SJ. eds. Hematopoi-
etic Cell Transplantation. Second Edition. Malden, MA: Black-
well Science; 1999, 431-443
24. Laughlin M, Rizzieri D, Smith CA, et al. Hematologic engraft-
ment and reconstitution of immune function post unrelated
placental cord blood transplant in an adult with acute lympho-
cytic leukemia. Leuk Res. 1998;22:215-219.
25. Hercend T, Takvorian T, Nowill A, et al. Characterization of
natural killer cells with antileukemia activity following alloge-
neic bone marrow transplantation. Blood. 1986;67:722-728.
26. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk
acute leukemia with T-cell depleted stem cells from related
donors with one fully mismatched HLA haplotype. N Engl
J Med. 1998;339:1186-1193.
27. Tcharmtchi MH, Smith CW, Mariscalco MM. Neonatal neu-
trophil interaction with P-selectin: contribution of P-selectin
glycoprotein ligand-1 and sialic acid. J Leukoc Biol. 2000;67:73-
80.
28. Levy O, Martin S, Eichenwald E, et al. Impaired innate immu-
nity in the newborn: newborn neutrophils are deﬁcient in
bactericidal/permeability-increasing protein. Pediatrics. 1999;
104:1327-1333.
29. Bracho F, Goldman S, Cairo M. Potential use of granulocyte
colony-stimulating factor and granulocyte-macrophage colony-
stimulating factor in neonates. Curr Opin Hematol. 1998;5:215-
220.
30. Przepiorka D, Ippoliti C, Khouri I, et al. Tacrolimus and
minidose methotrexate for prevention of acute graft-versus-
host disease after matched unrelated donor marrow transplan-
tation. Blood. 1996;88:4383-4389.
31. Przepiorka D, Petropoulos D, Mullen CA, et al. Tacrolimus for
prevention of graft-versus-host disease after mismatched unre-
lated donor cord blood transplantation. Bone Marrow Trans-
plant. 1999;23:1291-1295.
32. Shpall EJ, Quinones R, Giller R, et al. Transplantation of ex
vivo expanded cord blood. Biol Blood Marrow Transplant. 2002;
8:368-376.
33. Barker JN, Weisdorf DJ, DeFor TE, et al. Impact of multiple
unit unrelated donor umbilical cord blood transplantation in
adults: preliminary analysis of safety and efﬁcacy. Blood. 2001;
98:666a (abstr.).
G. D. Long et al.
780
